Impact of omalizumab on quality-of-life outcomes in patients with moderate-to-severe allergic asthma (Q36405257)

14 August 2017

0 references

1 reference

title

Impact of omalizumab on quality-of-life outcomes in patients with moderate-to-severe allergic asthma (English)

1 reference

14 August 2017

0 references

Julia Fox-Rushby

3

0 references

author name string

Kimberly Niebauer

series ordinal

1

1 reference

PubMed ID

16498854

14 August 2017

Sarah Dewilde

series ordinal

2

1 reference

PubMed ID

16498854

14 August 2017

Dennis A Revicki

series ordinal

4

1 reference

14 August 2017

1 February 2006

1 reference

Annals of Allergy, Asthma & Immunology

14 August 2017

1 reference

14 August 2017

96

1 reference

14 August 2017

2

1 reference

14 August 2017

316-326

1 reference

Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma.

14 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961242-2

7 January 2021

The role of allergy in the development of asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961242-2

7 January 2021

Association of asthma with serum IgE levels and skin-test reactivity to allergens

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961242-2

7 January 2021

The burden of asthma in the United States: level and distribution are dependent on interpretation of the national asthma education and prevention program guidelines.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961242-2

7 January 2021

Allergic rhinitis, rhinosinusitis, and asthma: one airway disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961242-2

7 January 2021

Epidemiologic evidence for asthma and rhinitis comorbidity.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961242-2

7 January 2021

The link between allergic rhinitis and allergic asthma: a prospective population-based study. The Copenhagen Allergy Study.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961242-2

7 January 2021

Treating the allergic patient: think globally, treat globally

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961242-2

7 January 2021

Rhinitis and asthma: evidence for respiratory system integration

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961242-2

7 January 2021

Allergic rhinitis in Rochester, Minnesota residents with asthma: frequency and impact on health care charges.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961242-2

7 January 2021

Treating allergic rhinitis in patients with comorbid asthma: the risk of asthma-related hospitalizations and emergency department visits

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961242-2

7 January 2021

Cross-sectional associations of asthma, hay fever, and other allergies with major depression and low-back pain among adults aged 20-39 years in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961242-2

7 January 2021

Inhaled salmeterol/fluticasone propionate combination: a pharmacoeconomic review of its use in the management of asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961242-2

7 January 2021

Impact of changes in asthma severity on health-related quality of life in pediatric and adult asthma patients: results from the asthma outcomes monitoring system.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961242-2

7 January 2021

Quality of life in adults and children with asthma and rhinitis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961242-2

7 January 2021

Quality of life in asthma clinical trials: comparison of salmeterol and salbutamol.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961242-2

7 January 2021

The unfavorable effects of concomitant asthma and sleeplessness due to the atopic eczema/dermatitis syndrome (AEDS) on quality of life in subjects allergic to house-dust mites.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961242-2

7 January 2021

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961242-2

1 reference

7 January 2021

The influence of co-morbidity on health-related quality of life in asthma and COPD patients

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961242-2

7 January 2021

A scale for assessing quality of life in adult asthma sufferers.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961242-2

7 January 2021

The St George's Respiratory Questionnaire

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961242-2

7 January 2021

Evaluation of impairment of health related quality of life in asthma: development of a questionnaire for use in clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961242-2

7 January 2021

A scale for the measurement of quality of life in adults with asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961242-2

7 January 2021

Evaluation of the Asthma Life Quality test for the screening and severity assessment of asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961242-2

7 January 2021

Association between preference-based health-related quality of life and asthma severity.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961242-2

7 January 2021

Omalizumab: a review of its use in the management of allergic asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961242-2

7 January 2021

Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961242-2

7 January 2021

Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961242-2

7 January 2021

The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961242-2

7 January 2021

Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961242-2

7 January 2021

Omalizumab improves asthma-related quality of life in patients with severe allergic asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961242-2

7 January 2021

Omalizumab (Xolair) improves quality of life in adult patients with allergic asthma: a review

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961242-2

7 January 2021

The anti-IgE antibody omalizumab improves asthma-related quality of life in patients with allergic asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961242-2

7 January 2021

Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab).

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961242-2

7 January 2021

Measuring quality of life in asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961242-2

7 January 2021

Psychometric performance of the Asthma Quality of Life Questionnaire in a US sample.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961242-2

7 January 2021

Interpreting treatment effects in randomised trials

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961242-2

7 January 2021

Asthma quality of life during 1 year of treatment with budesonide with or without formoterol.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961242-2

7 January 2021

Quality-of-life considerations in the treatment of asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961242-2

7 January 2021

Determining a minimal important change in a disease-specific Quality of Life Questionnaire.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961242-2

7 January 2021

A randomized trial comparing peak expiratory flow and symptom self-management plans for patients with asthma attending a primary care clinic.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961242-2

7 January 2021

Efficacy, safety, and effects on quality of life of salmeterol versus albuterol in patients with mild to moderate persistent asthma.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961242-2

7 January 2021

Using the standard error of measurement to identify important changes on the Asthma Quality of Life Questionnaire

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961242-2

7 January 2021

Anti-IgE: a significant breakthrough in the treatment of airway allergic diseases

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961242-2

7 January 2021

Pharmacoeconomic evaluation in the real world. Effectiveness versus efficacy studies

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961242-2

7 January 2021

Methods to explain the clinical significance of health status measures

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961242-2

7 January 2021

10.1016/S1081-1206(10)61242-2

Identifiers

DOI

1 reference

14 August 2017

1 reference

PubMed ID

16498854